Unique ID issued by UMIN | UMIN000009711 |
---|---|
Receipt number | R000011386 |
Scientific Title | The efficacy and safety of telaprevir-based triple therapy in elderly patients with HCV genotype 1 chronic hepatitis C, in comparison with the younger patients |
Date of disclosure of the study information | 2013/01/07 |
Last modified on | 2013/07/07 14:04:52 |
The efficacy and safety of telaprevir-based triple therapy in elderly patients with HCV genotype 1 chronic hepatitis C, in comparison with the younger patients
The efficacy and safety of telaprevir-based triple therapy in elderly patients with HCV genotype 1 chronic hepatitis C, in comparison with the younger patients
The efficacy and safety of telaprevir-based triple therapy in elderly patients with HCV genotype 1 chronic hepatitis C, in comparison with the younger patients
The efficacy and safety of telaprevir-based triple therapy in elderly patients with HCV genotype 1 chronic hepatitis C, in comparison with the younger patients
Japan |
Chronic hepatitis C
Medicine in general | Hepato-biliary-pancreatic medicine |
Others
NO
This study is done to evaluate the efficacy and tolerability of a triple therapy with telaprevir (TVR) added to pegylated interferon-alpha 2b and ribavirin in elderly patients.
Safety
TVR-based triple therapy can be used successfully and safely to treat elderly patients with genotype 1 chronic hepatitis C.
Observational
20 | years-old | <= |
Not applicable |
Male and Female
Adult patients with HCV genotype 1 chronic hepatitis C
Exclusion criteria were: (1) positivity for antibody to human immunodeficiency virus or positivity for hepatitis B surface antigen; (2) clinical or biochemical evidence of hepatic decompensation (ascites, bleeding varices, or encephalopathy); (3) other causes of liver disease (autoimmune hepatitis, primary biliary cirrhosis, or steatohepatitis); (4) excessive active alcohol consumption (a daily intake of more than 40 g of ethanol) or drug abuse; (5) suspected HCC at entry; or (6) treatment with antiviral or immunosuppressive agents prior to enrollment.
400
1st name | |
Middle name | |
Last name | Jun Hayashi |
Kyushu University Hospital
Department of General Internal Medicine
3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan
092-642-5908
1st name | |
Middle name | |
Last name | Norihiro Furusyo |
Kyushu University Hospital
Department of General Internal Medicine
3-1-1, Maidashi, Higashi-Ku, Fukuoka, 812-8582, Japan
092-642-5909
Kyushu University Hospital
Kyushu University Hospital
NO
2013 | Year | 01 | Month | 07 | Day |
Partially published
Completed
2011 | Year | 12 | Month | 01 | Day |
2011 | Year | 12 | Month | 01 | Day |
2013 | Year | 07 | Month | 01 | Day |
2013 | Year | 07 | Month | 01 | Day |
2013 | Year | 07 | Month | 01 | Day |
2013 | Year | 07 | Month | 08 | Day |
TVR-based triple therapy can be used successfully and safely to treat elderly patients with genotype 1 chronic hepatitis C.
2013 | Year | 01 | Month | 07 | Day |
2013 | Year | 07 | Month | 07 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011386
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |